Total Payments
$7,672
2024 Payments
$16.07
Companies
35
Transactions
239
Medicare Patients
3,873
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$5,062 (66.0%)
Other$2,500 (32.6%)
Education$110.06 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,062 | 233 | 66.0% |
| Honoraria | $2,500 | 1 | 32.6% |
| Education | $110.06 | 5 | 1.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| NanoString Technologies, Inc. | $2,718 | 4 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $544.82 | 32 | $0 (2021) |
| Amgen Inc. | $533.44 | 24 | $0 (2021) |
| Eisai Inc. | $441.23 | 16 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $430.06 | 23 | $0 (2023) |
| TESARO, Inc. | $333.42 | 8 | $0 (2018) |
| Genentech USA, Inc. | $317.75 | 17 | $0 (2021) |
| Foundation Medicine, Inc. | $247.32 | 14 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $203.79 | 11 | $0 (2021) |
| PFIZER INC. | $169.50 | 11 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16.07 | 1 | Gilead Sciences, Inc. ($16.07) |
| 2023 | $56.06 | 2 | Novartis Pharmaceuticals Corporation ($56.06) |
| 2022 | $237.88 | 6 | Janssen Scientific Affairs, LLC ($140.53) |
| 2021 | $508.10 | 28 | Seagen Inc. ($70.04) |
| 2020 | $545.04 | 31 | AstraZeneca Pharmaceuticals LP ($124.42) |
| 2019 | $1,438 | 74 | Amgen Inc. ($269.35) |
| 2018 | $1,020 | 50 | Eisai Inc. ($150.23) |
| 2017 | $3,852 | 47 | NanoString Technologies, Inc. ($2,718) |
All Payment Transactions
239 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/31/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: ONC | ||||||
| 11/15/2023 | Novartis Pharmaceuticals Corporation | TABRECTA (Drug) | Food and Beverage | In-kind items and services | $29.71 | General |
| Category: Oncology | ||||||
| 08/24/2023 | Novartis Pharmaceuticals Corporation | TABRECTA (Drug) | Food and Beverage | In-kind items and services | $26.35 | General |
| Category: Oncology | ||||||
| 09/13/2022 | Janssen Scientific Affairs, LLC | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $113.45 | General |
| Category: Oncology | ||||||
| 09/12/2022 | Janssen Scientific Affairs, LLC | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $27.08 | General |
| Category: Oncology | ||||||
| 01/05/2022 | MAYNE PHARMA INC. | — | Food and Beverage | In-kind items and services | $25.74 | General |
| 01/05/2022 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: ONCOLOGY | ||||||
| 01/04/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: ONCOLOGY | ||||||
| 01/01/2022 | GE HealthCare | — | Food and Beverage | Cash or cash equivalent | $30.45 | General |
| 12/16/2021 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $23.43 | General |
| 12/16/2021 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2021 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $21.42 | General |
| Category: Oncology | ||||||
| 11/11/2021 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $20.68 | General |
| Category: Oncology | ||||||
| 11/02/2021 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2021 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: Oncology | ||||||
| 09/02/2021 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: Oncology | ||||||
| 08/18/2021 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $23.24 | General |
| Category: ONC | ||||||
| 08/10/2021 | Mylan Institutional Inc. | Ogivri (Drug), Fulphila | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: Trastuzumab injection | ||||||
| 07/29/2021 | Foundation Medicine, Inc. | FOUNDATIONONE (Device), FOUNDATIONONE HEME, FOUNDATIONONE CDX | Food and Beverage | In-kind items and services | $20.01 | General |
| Category: ONCOLOGY | ||||||
| 07/27/2021 | NOVARTIS PHARMACEUTICALS CORPORATION | KISQALI (Drug), FEMARA, PIQRAY | Food and Beverage | In-kind items and services | $20.67 | General |
| Category: ONCOLOGY | ||||||
| 07/20/2021 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: ONCOLOGY | ||||||
| 06/10/2021 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $27.07 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/06/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LENVIMA | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: ONCOLOGY | ||||||
| 04/22/2021 | Eisai Inc. | Halaven (Drug) | Food and Beverage | Cash or cash equivalent | $19.13 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 746 | 6,700 | $809,068 | $181,716 |
| 2022 | 9 | 789 | 6,408 | $789,712 | $171,304 |
| 2021 | 10 | 851 | 6,133 | $695,857 | $209,510 |
| 2020 | 17 | 1,487 | 21,247 | $1.6M | $613,303 |
Total Patients
3,873
Total Services
40,488
Medicare Billing
$1.2M
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 405 | 797 | $229,536 | $78,915 | 34.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 21 | 3,420 | $140,220 | $62,169 | 44.3% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 19 | 1,900 | $364,800 | $18,125 | 5.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 122 | 142 | $28,826 | $8,325 | 28.9% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 25 | 208 | $23,296 | $6,377 | 27.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 21 | 21 | $10,248 | $3,687 | 36.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 22 | 22 | $8,140 | $2,649 | 32.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 85 | 137 | $822.00 | $805.56 | 98.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 26 | 53 | $3,180 | $663.52 | 20.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 394 | 704 | $202,752 | $69,822 | 34.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 24 | 3,120 | $127,920 | $53,863 | 42.1% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2022 | 18 | 1,940 | $370,560 | $19,512 | 5.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 160 | 194 | $39,382 | $13,328 | 33.8% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 26 | 222 | $24,864 | $6,644 | 26.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 25 | 26 | $10,400 | $3,925 | 37.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $8,296 | $2,858 | 34.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 43 | 82 | $4,920 | $1,046 | 21.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 82 | 103 | $618.00 | $305.28 | 49.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 306 | 542 | $156,049 | $60,996 | 39.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 26 | 3,210 | $126,690 | $51,750 | 40.8% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2021 | 23 | 1,530 | $282,240 | $49,433 | 17.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 315 | 420 | $85,260 | $33,270 | 39.0% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2021 | 34 | 228 | $25,536 | $6,862 | 26.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 18 | 18 | $8,784 | $3,513 | 40.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 11 | 12 | $4,800 | $1,921 | 40.0% |
About Dr. John Link, MD
Dr. John Link, MD is a Specialist healthcare provider based in Orange, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245281211.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Link, MD has received a total of $7,672 in payments from pharmaceutical and medical device companies, with $16.07 received in 2024. These payments were reported across 239 transactions from 35 companies. The most common payment nature is "Food and Beverage" ($5,062).
As a Medicare-enrolled provider, Link has provided services to 3,873 Medicare beneficiaries, totaling 40,488 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Orange, CA
- Active Since 05/15/2006
- Last Updated 05/26/2021
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1245281211
Products in Payments
- PROSIGNA ASSAY (Device) $2,718
- Halaven (Drug) $427.00
- LYNPARZA (Drug) $296.44
- Perjeta (Biological) $260.90
- ZEJULA (Drug) $251.63
- FOUNDATIONONE (Device) $209.67
- KISQALI (Drug) $204.49
- IBRANCE (Drug) $169.50
- FASLODEX (Drug) $160.80
- IMBRUVICA (Drug) $140.53
- SPY Technology (Device) $139.78
- Prolia (Biological) $138.27
- Neulasta (Biological) $136.16
- ZOLADEX (Drug) $116.52
- PIQRAY (Drug) $110.11
- KEYTRUDA (Biological) $108.66
- Abraxane (Drug) $103.96
- KANJINTI (Biological) $103.12
- TUKYSA (Drug) $101.09
- VARUBI (Drug) $81.79
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Orange
Andrew Cassidenti, M.d, M.D
Specialist — Payments: $83,590
Specialist $83,590
Dr. Steve Mora, M.d, M.D
Specialist — Payments: $54,129
Specialist $54,129
Dr. Brian Palafox, M.d, M.D
Specialist — Payments: $53,229
Specialist $53,229
Dr. Samuel Rosenfeld, M.d, M.D
Specialist — Payments: $47,823
Specialist $47,823
Dr. Thomas Kim, M.d, M.D
Specialist — Payments: $47,716
Specialist $47,716
Gerald Alexander, M.d, M.D
Specialist — Payments: $45,760
Specialist $45,760